Humabs Biomed S.A.
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Methods of generating robust passive and active immune responses (US 10,335,484) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 2 fees due Feb 15 to 22, 2027 · next Feb 15
- 1 fee due Apr 17, 2027The maintenance fee for Neutralizing Anti-Influenza B Antibodies and Uses Thereof (US 11,787,853) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 2 fees due Jun 3 to 30, 2027 · next Jun 3
- 1 fee due Aug 27, 2027The maintenance fee for Novel Antibodies Specifically Binding to Zika Virus Epitopes and Uses Thereof (US 11,912,757) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 2 fees due Sep 12 to 19, 2027 · next Sep 12
Recent changes
- 2 terms have ended since Aug 23, 2026
- Sep 11 US 10,072,071 Antibodies That Neutralize RSV, MPV and PVM and Uses Thereof · lapsed on the fee record
- Aug 23 US 11,421,020 Antibodies That Neutralize RSV, MPV and PVM and Uses Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,498,531 | Antibodies That Neutralize RSV, MPV and PVM and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,335,484 | Methods of generating robust passive and active immune responses In force · USPTO record | In force | USPTO record | |
| US 10,329,342 | Antibodies That Potently Neutralize RSV and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,186,627 | Neutralizing Anti-Influenza a Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,932,682 | Neutralizing Anti-Influenza a Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,492,240 | Neutralizing Anti-Influenza a Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,047,145 | Antibodies That Potently Neutralize RSV and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,294,292 | Neutralizing Anti-Influenza B Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,519,221 | Neutralizing Anti-Influenza B Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,174,304 | Neutralizing Anti-Influenza B Antibodies and Uses Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 24: 13 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 5 abandoned · 3 no status recorded